The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
Open accessAbstract
The sudden emergence of severe respiratory disease, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health emergency. Genome sequence analysis of SARS-CoV-2 revealed its close resemblance to the earlier reported SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). However, initial testing of the drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. The present study highlights the genomic, proteomic, pathogenesis, and therapeutic strategies in SARS-CoV-2 infection. We have carried out sequence analysis of potential drug target proteins in SARS-CoV-2 and, compared them with SARS-CoV and MERS viruses. Analysis of mutations in the coding and non-coding regions, genetic diversity, and pathogenicity of SARS-CoV-2 has also been done. A detailed structural analysis of drug target proteins has been performed to gain insights into the mechanism of pathogenesis, structure-function relationships, and the development of structure-guided therapeutic approaches. The cytokine profiling and inflammatory signalling are different in the case of SARS-CoV-2 infection. We also highlighted possible therapies and their mechanism of action followed by clinical manifestation. Our analysis suggests a minimal variation in the genome sequence of SARS-CoV-2, may be responsible for a drastic change in the structures of target proteins, which makes available drugs ineffective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Research works printed but not linked: 20
- Lu, 2015, Complete genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) from the first imported MERS-CoV case in China, Genome Announc., 3, 10.1128/genomeA.00818-15 · doi:10.1128/genomea.00818-15
- Graham, 2020, SARS-CoV-2: Combating Coronavirus Emergence, Immunity, 52, 734, 10.1016/j.immuni.2020.04.016 · doi:10.1016/j.immuni.2020.04.016
- Nishikiori, 2012, Crystal structure of the superfamily 1 helicase from tomato mosaic virus, J. Virol., 86, 7565, 10.1128/JVI.00118-12 · doi:10.1128/jvi.00118-12
- van Dinten, 2000, The predicted metal-binding region of the arterivirus helicase protein is involved in subgenomic mRNA synthesis, genome replication, and virion biogenesis, J. Virol., 74, 5213, 10.1128/JVI.74.11.5213-5223.2000 · doi:10.1128/jvi.74.11.5213-5223.2000
- Bomma, 2012, PONDR (predicators of natural disorder regions), International Journal of Computer Technology and Electronics Engineering, 21, 61
- Minakshi, 2014, The SARS coronavirus 3a protein binds calcium in its cytoplasmic domain, Virus Res., 191, 180, 10.1016/j.virusres.2014.08.001 · doi:10.1016/j.virusres.2014.08.001
- Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
- Hassan, 2016, Editorial. Recent advances in the structure-based drug design and discovery, Curr. Top. Med. Chem., 16, 899, 10.2174/1568026616999150918145640 · doi:10.2174/1568026616999150918145640
- Greene, 2020, Innate immunity of the lung, Journal of Innate Immunity, 12, 1, 10.1159/000504621 · doi:10.1159/000504621
- Guastalegname, 2020, Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?, Clin. Infect. Dis., ciaa321
- Elfiky, 2020, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study, Life Sci., 117592
- Zumla, 2016, Coronaviruses—drug discovery and therapeutic options, Nat. Rev. Drug Discov., 15, 327, 10.1038/nrd.2015.37 · DOI · Paper page
- Schlagenhauf, 2020, Repurposing antimalarials and other drugs for COVID-19, Travel Med. Infect. Dis., 34, 101658, 10.1016/j.tmaid.2020.101658 · doi:10.1016/j.tmaid.2020.101658
- Hong, 2020, Combating COVID-19 with chloroquine, J Mol Cell Biol, 12, 249, 10.1093/jmcb/mjaa015 · doi:10.1093/jmcb/mjaa015
- Cao, 2020, COVID-19: immunopathology and its implications for therapy, Nat Rev Immunol, 20, 269, 10.1038/s41577-020-0308-3 · DOI · Paper page
- Duan, 2019, COVID-19 and its research progress in forensic toxicology, Fa Yi Xue Za Zhi, 36
- FitzGerald, 2020, Misguided drug advice for COVID-19, Science, 367, 1434, 10.1126/science.abb8034 · DOI · Paper page
- Orleans, 2020, Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The case for compassionate use, Pain Physician, 23, E71
- Wang, 2005, Study on the resistance of severe acute respiratory syndrome-associated coronavirus, J. Virol. Methods, 126, 171, 10.1016/j.jviromet.2005.02.005 · doi:10.1016/j.jviromet.2005.02.005
- Shamsi, 2020, Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy, Bioscience Reports, 40, 10.1042/BSR20201256 · DOI · Paper page
Cited by
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P., & Cao, J.-M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.587269 · Cited by 874
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
Yadav, R., Chaudhary, J. K., Jain, N., Chaudhary, P. K., Khanra, S., Dhamija, P., Sharma, A., Kumar, A., & Handu, S. (2021) · Cells · doi:10.3390/cells10040821 · Cited by 451
COVID-19: Virology, biology and novel laboratory diagnosis
Mohamadian, M., Chiti, H., Shoghli, A., Biglari, S., Parsamanesh, N., & Esmaeilzadeh, A. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3303 · Cited by 371
Metadata
- Authors
- Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 1866
- Issue
- 10
- Pages
- 165878
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W3035265089
- Cited by
- 1,114
- References
- 140
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- Indian Council of Medical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. https://app.cochat.ai/papers/10.1016/j.bbadis.2020.165878
- The paper
- Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2020.165878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
